Biotronik touted long-term safety and efficacy data for its Orsiro drug-eluting stent yesterday at this year’s Transcatheter Cardiovascular Therapeutics meeting.
Data from the Bioflow-II trial and the Bioflow-III registry demonstrated that Biotroniks’s device boasts strong safety and clinical performance at five years, the company reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Biotronik’s Orsiro drug-eluting stent succeeds at five-year follow-up appeared first on MassDevice.